TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)
Brief Summary: The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)
D: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)
Brief Summary: The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.


Options:
A: Arm Label: PROOF cohort; Type: N/A; Interventions: Other: Sleep apnea/hypopnea detection | Intervention Type: OTHER; Name: Sleep apnea/hypopnea detection; Assigned to Arm(s): PROOF cohort
B: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)
C: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Dose adjustment of nicotine replacement therapies | Arm Label: 2; Type: OTHER; Interventions: Drug: nicotine patch | Intervention Type: PROCEDURE; Name: Dose adjustment of nicotine replacement therapies; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)
Brief Summary: The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.


Options:
A: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Edwards SAPIEN XT Transcatheter Heart Valve Therapy for Intermediate and High Risk Patients
Brief Summary: The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN XT transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.


Options:
A: Arm Label: Medtronic Transcatheter Aortic Valve Replacement Systems; Type: EXPERIMENTAL; Interventions: Device: Medtronic Transcatheter Aortic Valve Replacement Systems | Arm Label: Surgical Aortic Valve Replacement (SAVR); Type: ACTIVE_COMPARATOR; Interventions: Device: Surgical Aortic Valve Replacement (SAVR) | Intervention Type: DEVICE; Name: Medtronic Transcatheter Aortic Valve Replacement Systems; Assigned to Arm(s): Medtronic Transcatheter Aortic Valve Replacement Systems | Intervention Type: DEVICE; Name: Surgical Aortic Valve Replacement (SAVR); Assigned to Arm(s): Surgical Aortic Valve Replacement (SAVR)
B: Arm Label: Medtronic CoreValve® System TAVI; Type: EXPERIMENTAL; Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI) | Arm Label: SAVR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical Aortic Valve Replacement (SAVR) | Intervention Type: DEVICE; Name: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Assigned to Arm(s): Medtronic CoreValve® System TAVI | Intervention Type: PROCEDURE; Name: Surgical Aortic Valve Replacement (SAVR); Assigned to Arm(s): SAVR | Intervention Type: DEVICE; Name: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI); Assigned to Arm(s): Medtronic CoreValve® System TAVI
C: Arm Label: PIIA - SAPIEN XT; Type: EXPERIMENTAL; Interventions: Device: TAVR Implantation with SAPIEN XT | Arm Label: Control: SAVR; Type: ACTIVE_COMPARATOR; Interventions: Device: SAVR Implantation | Intervention Type: DEVICE; Name: TAVR Implantation with SAPIEN XT; Assigned to Arm(s): PIIA - SAPIEN XT | Intervention Type: DEVICE; Name: SAVR Implantation; Assigned to Arm(s): Control: SAVR
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Edwards SAPIEN Transcatheter Heart Valve | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Surgical Valve Replacement | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: Edwards SAPIEN Transcatheter Heart Valve | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Other: medical management and/or balloon aortic valvuloplasty | Intervention Type: DEVICE; Name: Edwards SAPIEN Transcatheter Heart Valve; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Surgical Valve Replacement; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: medical management and/or balloon aortic valvuloplasty; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DYSPORT™ for Injection AbobotulinumtoxinA Neurotoxin Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD)
Brief Summary: The purpose of the protocol is to determine typical patient response to Dysport in the treatment of adult cervical dystonia (CD).


Options:
A: Arm Label: Dysport NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Dysport; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport NG | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: N/A
C: Arm Label: Dysport®; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dysport; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)
Brief Summary: The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)
Brief Summary: The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
B: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
C: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)
Brief Summary: The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
B: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)
Brief Summary: The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: Cohort A (3 capsules o.d.): TIP; Type: EXPERIMENTAL; Interventions: Drug: TIP | Arm Label: Cohort A (3 capsules o.d.): TIP/PBO; Type: EXPERIMENTAL; Interventions: Drug: TIP and placebo | Arm Label: Cohort A (3 capsules o.d.): PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort B (5 capsules o.d.): TIP; Type: EXPERIMENTAL; Interventions: Drug: TIP | Arm Label: Cohort B (5 capsules o.d.): TIP/PBO; Type: EXPERIMENTAL; Interventions: Drug: TIP and placebo | Arm Label: Cohort B (5 capsules o.d.): PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort C (4 capsules b.i.d.): TIP; Type: EXPERIMENTAL; Interventions: Drug: TIP | Arm Label: Cohort C (4 capsules b.i.d.): TIP/PBO; Type: EXPERIMENTAL; Interventions: Drug: TIP and placebo | Arm Label: Cohort C (4 capsules b.i.d.): PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TIP; Assigned to Arm(s): Cohort A (3 capsules o.d.): TIP, Cohort B (5 capsules o.d.): TIP, Cohort C (4 capsules b.i.d.): TIP | Intervention Type: DRUG; Name: TIP and placebo; Assigned to Arm(s): Cohort A (3 capsules o.d.): TIP/PBO, Cohort B (5 capsules o.d.): TIP/PBO, Cohort C (4 capsules b.i.d.): TIP/PBO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A (3 capsules o.d.): PBO, Cohort B (5 capsules o.d.): PBO, Cohort C (4 capsules b.i.d.): PBO
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Radiographic Comparison and Evaluation of Two Types of Lingual Fixed Retainers on the Health of Periodontium
Brief Summary: Different types of retainers have been used to assure the stability of orthodontic treatment. The aim of this study is clinical and radiographic comparison and evaluation of two common types of lingual fixed retainers on the health of periodontium.

The participants in this study will be examined both clinically and radiographically just after the completion of orthodontic treatment and after a 6-month-period.

The results of the study will be analyzed with Mann-whitney and independent t-test.


Options:
A: Arm Label: Thermoplastic Retainer; Type: EXPERIMENTAL; Interventions: Other: orthodontic appliance | Arm Label: Hawley Retainer; Type: ACTIVE_COMPARATOR; Interventions: Other: orthodontic appliance | Intervention Type: OTHER; Name: orthodontic appliance; Assigned to Arm(s): Hawley Retainer, Thermoplastic Retainer
B: Arm Label: Receive electronic reminder; Type: EXPERIMENTAL; Interventions: Other: Electronic reminder | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic reminder; Assigned to Arm(s): Receive electronic reminder
C: Arm Label: Conventional; Type: EXPERIMENTAL; Interventions: Device: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model | Arm Label: 3D; Type: EXPERIMENTAL; Interventions: Device: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model | Intervention Type: DEVICE; Name: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model; Assigned to Arm(s): 3D, Conventional
D: Arm Label: Fiber-reinforced-composite retainer; Type: ACTIVE_COMPARATOR; Interventions: Device: Fiber-reinforced-composite retainer | Arm Label: composite-wire retainer; Type: ACTIVE_COMPARATOR; Interventions: Device: Composite-wire retainer | Intervention Type: DEVICE; Name: Fiber-reinforced-composite retainer; Assigned to Arm(s): Fiber-reinforced-composite retainer | Intervention Type: DEVICE; Name: Composite-wire retainer; Assigned to Arm(s): composite-wire retainer

Answer: D